 | Up a level |
Andreadis, C., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Foley, S. R., Westin, J. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Salles, G. A., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Wagner-Johnston, N. D., Kato, K., Corradini, P., Tiwari, R., Awasthi, R., Lawniczek, T., Eldjerou, L. K. and Kersten, M. J. (2020). Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel. Oncol. Res. Treat., 43 (SUPPL 4). S. 62 - 64. BASEL: KARGER. ISSN 2296-5262
Borchmann, P., Tam, C. S., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S. M., Bishop, M. R., Andreadis, C., Foley, S. R., Westin, J. R., Fleury, I., Ho, P. J., Mielke, S., Salles, G., Maziarz, R. T., Anak, Oe, Pacaud, L. B., del Corral, C., Awasthi, R., Agoulnik, S., Tai, F. and Schuster, S. J. (2018). An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Oncol. Res. Treat., 41. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262
Westin, J., Tam, C. S., Borchmann, P., Jaeger, U., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Andreadis, C., Foley, S. R., Fleury, I, Ho, P. J., Mielke, S., Teshima, T., Schuster, S. J., Bachanova, V, Maziarz, R. T., Besien, K., V, Izutsu, K., Kersten, M. J., Wagner-Johnston, N. D., Kato, K., Corradini, P., Han, X., Tiwari, R., Eldjerou, L. K., Pacaud, L. B. and Salles, G. A. (2020). Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 58 - 59. BASEL: KARGER. ISSN 2296-5262